Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Cordlife Group ( (SG:P8A) ).
Cordlife Group Limited has received a one-year renewal of its cord blood and human tissue banking service licenses from the Ministry of Health in Singapore, effective 14 January 2025. The company is committed to complying with regulatory requirements before fully resuming operations, and until then, stakeholders are advised to exercise caution in their dealings with the company’s shares.
More about Cordlife Group
Cordlife Group Limited, registered in Singapore, operates in the healthcare industry, focusing on cord blood banking and human tissue banking services.
YTD Price Performance: 0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $27.96M
For detailed information about P8A stock, go to TipRanks’ Stock Analysis page.
